Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Regeneron Pharmaceuticals (NQ:REGN)

635.17 -7.42 (-1.15%)
Streaming Delayed Price Updated: 2:24 PM EDT, May 22, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Regeneron Pharmaceuticals

< Previous 1 2
...
20 21 22 23 24 25 26 27 28
...
62 63 Next >
News headline image
Beyond The Numbers: 20 Analysts Discuss Regeneron Pharmaceuticals Stock ↗
 
Via Benzinga
News headline image
Regeneron to Highlight Progress Across Its Differentiated Oncology Portfolio and Pipeline at WCLC and ESMO
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Prediction: These 2 Cathie Wood Stocks Could Crush the Market Through 2030 ↗
These stocks have generally delivered competitive returns. 
Via The Motley Fool
News headline image
Biotech And Life Science Sector Update Summer Of 2024 ↗
It’s the slowest week of the year, we are at the market top and most earnings reports are good. 
Via Talk Markets
News headline image
Evaluating Regeneron Pharmaceuticals Against Peers In Biotechnology Industry ↗
 
Via Benzinga
News headline image
What Analysts Are Saying About Regeneron Pharmaceuticals Stock ↗
 
Via Benzinga
News headline image
If You Invested $1000 In This Stock 20 Years Ago, You Would Have $130 Thousand Today ↗
 
Via Benzinga
News headline image
Insights Into Regeneron Pharmaceuticals's Performance Versus Peers In Biotechnology Sector ↗
 
Via Benzinga
News headline image
$100 Invested In This Stock 20 Years Ago Would Be Worth $15,000 Today ↗
 
Via Benzinga
News headline image
Ordspono™ (odronextamab) Approved in the European Union for the Treatment of Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Latest Dupixent® (dupilumab) and Itepekimab Data at ERS Highlight Scientific Innovation and Leadership in Respiratory Diseases
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
10 Bagger Stocks: Can You Find One? ↗
Finding 10 baggers is not easy, but it’s a worthwhile pursuit for long-term investors. 
Via Talk Markets
News headline image
Regeneron Faces Setback With FDA Rejection Of Blood-Cancer Treatment ↗
Regeneron Pharmaceuticals Inc. has received a setback as the Food and Drug Administration has declined its application for a blood cancer treatment. 
Via Benzinga
News headline image
Analyst Ratings For Regeneron Pharmaceuticals ↗
 
Via Benzinga
News headline image
Regeneron Provides Update on Biologics License Application for Linvoseltamab
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Biotech Bull Market: 3 Ways To Play It ↗
Although we are in the later stages of this bull market a cut in interest rates by the Fed should help biotech as you have seen from the recent rally. 
Via Talk Markets
Topics Economy
News headline image
Alphabet Turns Twenty ↗
Twenty years ago to the day, the company running the world's largest search engine went public. On August 19th, 2004, Alphabet shares IPO'd at a split-adjusted price of $2.13. 
Via Talk Markets
News headline image
7 Stocks That Usually Benefit From a Recession ↗
These seven stocks have historically shown resilience during economic downturns and could potentially benefit from a recession. 
Via InvestorPlace
News headline image
3 Biotech Stocks Poised for a Comeback After Last Week’s Market Meltdown ↗
Investors should closely watch these three biotech stocks as their strong prospects are likely to help the rebound from market volatility. 
Via InvestorPlace
News headline image
3 Biotech Stocks With Promising Drug Pipelines: August 2024 ↗
The biotech stocks with promising pipelines could see shares soar if drugs in late-stage trials get FDA approval. 
Via InvestorPlace
News headline image
Regeneron Announces Investor Conference Presentations and Oncology Investor Webcast
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
3 Healthcare Stocks Positioned for Possible Market Outperformance ↗
While healthcare stocks might not be as shiny as they were in the pandemic era, these three could outperform the broader market. 
Via InvestorPlace
News headline image
Is Regeneron Pharmaceuticals Due for a Stock Split? ↗
Would a stock split help lead Regeneron Pharmaceuticals shares higher? 
Via The Motley Fool
News headline image
Stock Market Takes Bearish Turn; Apple, Microsoft, Meta, Amazon, AMD In Focus: Weekly Review ↗
Apple and Meta had strong results, while AI spending remains robust. 
Via Investor's Business Daily
Topics Artificial Intelligence
News headline image
Regeneron Pharmaceuticals' Q2 Earnings Exceed Estimates, Driven By Its Top-Selling Eczema And Eye Drugs ↗
Regeneron Pharmaceuticals Q2 results: adjusted EPS of $11.56 (up 13%), revenue of $3.55 billion (up 12%). Key drivers: Eylea HD, Dupixent, and Libtayo. Notable: 18% decline in Eylea US sales; 42%... 
Via Benzinga
News headline image
Regeneron Stock Climbs After Strong Second-Quarter Performance ↗
A strong second-quarter performance lifted the already extended shares of the New York-based drug maker Regeneron. 
Via Investor's Business Daily
News headline image
Regeneron Reports Second Quarter 2024 Financial and Operating Results
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
US Stocks Tumble On Economic, Geopolitical Concerns; Small Caps, Chipmakers Sink; Meta Rallies: What's Driving Markets Thursday? ↗
Markets experienced a sharp downturn, driven by heightened geopolitical tensions and economic uncertainties that negatively impacted investor risk sentiment, just a day after the Federal Open Market... 
Via Benzinga
News headline image
Regeneron Announces the 2024 Winners of the Regeneron Prize for Creative Innovation
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Wall Street Looks To Ride On Earnings Cheer As Meta Q2 Impresses Investors: Analyst Says Economic Data, Stock Performances Suggest Republican Win In November ↗
After Wednesday’s tech-led rebound amid the Federal Reserve’s rate decision, the stock market could be in for further gains. The major index futures point to a higher opening, although suggesting a... 
Via Benzinga
< Previous 1 2
...
20 21 22 23 24 25 26 27 28
...
62 63 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.